These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 12853790)

  • 21. Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma.
    Meyer HA; Tölle A; Jung M; Fritzsche FR; Haendler B; Kristiansen I; Gaspert A; Johannsen M; Jung K; Kristiansen G
    Eur Urol; 2009 Mar; 55(3):669-78. PubMed ID: 18450365
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Papillary type 2 versus clear cell renal cell carcinoma: Survival outcomes.
    Simone G; Tuderti G; Ferriero M; Papalia R; Misuraca L; Minisola F; Costantini M; Mastroianni R; Sentinelli S; Guaglianone S; Gallucci M
    Eur J Surg Oncol; 2016 Nov; 42(11):1744-1750. PubMed ID: 27593224
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy.
    Sejima T; Morizane S; Hinata N; Yao A; Isoyama T; Saito M; Takenaka A
    Urol Int; 2012; 88(3):263-70. PubMed ID: 22398398
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CXC chemokine receptor 2 is associated with postoperative recurrence and survival of patients with non-metastatic clear-cell renal cell carcinoma.
    An H; Xu L; Chang Y; Zhu Y; Yang Y; Chen L; Lin Z; Xu J
    Eur J Cancer; 2015 Sep; 51(14):1953-61. PubMed ID: 26188847
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Limited prognostic value of tumor necrosis in patients with renal cell carcinoma.
    Isbarn H; Patard JJ; Lughezzani G; Rioux-Leclercq N; Crépel M; Cindolo L; de la Taille A; Zini L; Villers A; Shariat SF; Bertini R; Karakiewicz PI
    Urology; 2010 Jun; 75(6):1378-84. PubMed ID: 19781745
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The effect of gender and age on kidney cancer survival: younger age is an independent prognostic factor in women with renal cell carcinoma.
    Rampersaud EN; Klatte T; Bass G; Patard JJ; Bensaleh K; Böhm M; Allhoff EP; Cindolo L; De La Taille A; Mejean A; Soulie M; Bellec L; Christophe Bernhard J; Pfister C; Colombel M; Belldegrun AS; Pantuck AJ; George D
    Urol Oncol; 2014 Jan; 32(1):30.e9-13. PubMed ID: 23422777
    [TBL] [Abstract][Full Text] [Related]  

  • 28. External validation of the Mayo Clinic stage, size, grade, and necrosis (SSIGN) score for clear-cell renal cell carcinoma in a single European centre applying routine pathology.
    Zigeuner R; Hutterer G; Chromecki T; Imamovic A; Kampel-Kettner K; Rehak P; Langner C; Pummer K
    Eur Urol; 2010 Jan; 57(1):102-9. PubMed ID: 19062157
    [TBL] [Abstract][Full Text] [Related]  

  • 29. External validation of the Mayo Clinic Stage, Size, Grade and Necrosis (SSIGN) score to predict cancer specific survival using a European series of conventional renal cell carcinoma.
    Ficarra V; Martignoni G; Lohse C; Novara G; Pea M; Cavalleri S; Artibani W
    J Urol; 2006 Apr; 175(4):1235-9. PubMed ID: 16515968
    [TBL] [Abstract][Full Text] [Related]  

  • 30. External validation of the Mayo Clinic cancer specific survival score in a Japanese series of clear cell renal cell carcinoma.
    Fujii Y; Saito K; Iimura Y; Sakai Y; Koga F; Kawakami S; Kumagai J; Kihara K
    J Urol; 2008 Oct; 180(4):1290-5; discussion 1295-6. PubMed ID: 18707704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A scoring algorithm to predict survival for patients with metastatic clear cell renal cell carcinoma: a stratification tool for prospective clinical trials.
    Leibovich BC; Cheville JC; Lohse CM; Zincke H; Frank I; Kwon ED; Merchan JR; Blute ML
    J Urol; 2005 Nov; 174(5):1759-63; discussion 1763. PubMed ID: 16217278
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term survival of patients with unilateral sporadic multifocal renal cell carcinoma according to histologic subtype compared with patients with solitary tumors after radical nephrectomy.
    Dimarco DS; Lohse CM; Zincke H; Cheville JC; Blute ML
    Urology; 2004 Sep; 64(3):462-7. PubMed ID: 15351571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic value of interleukin-6 and interleukin-6 receptor in organ-confined clear-cell renal cell carcinoma: a 5-year conditional cancer-specific survival analysis.
    Fu Q; Chang Y; An H; Fu H; Zhu Y; Xu L; Zhang W; Xu J
    Br J Cancer; 2015 Dec; 113(11):1581-9. PubMed ID: 26554658
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel prognostic model for patients with sarcomatoid renal cell carcinoma.
    Zhang BY; Thompson RH; Lohse CM; Leibovich BC; Boorjian SA; Cheville JC; Costello BA
    BJU Int; 2015 Mar; 115(3):405-11. PubMed ID: 24730416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
    Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
    Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 expression in renal cell carcinoma clear cell type is related to unfavorable prognosis.
    Leite KR; Reis ST; Junior JP; Zerati M; Gomes Dde O; Camara-Lopes LH; Srougi M
    Diagn Pathol; 2015 Oct; 10():189. PubMed ID: 26470780
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
    Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
    Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chromophobe renal cell carcinoma: the impact of tumor grade on outcome.
    Cheville JC; Lohse CM; Sukov WR; Thompson RH; Leibovich BC
    Am J Surg Pathol; 2012 Jun; 36(6):851-6. PubMed ID: 22367296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of beta-blockers and survival among hypertensive patients with renal cell carcinoma.
    Parker WP; Lohse CM; Zaid HB; Cheville JC; Boorjian SA; Leibovich BC; Thompson RH
    Urol Oncol; 2017 Jan; 35(1):36.e1-36.e6. PubMed ID: 27687543
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.